• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,563.92 -1,470.50
( -1.93%)
Global Indices
Nasdaq
46,583.62 -115.24
(-0.25%)
Dow Jones
6,653.27 -40.35
(-0.60%)
Hang Seng
53,838.16 -614.80
(-1.13%)
Nikkei 225
10,249.42 -55.73
(-0.54%)
Forex
USD-INR
92.29 0.37
(0.40%)
EUR-INR
106.44 -0.15
(-0.14%)
GBP-INR
123.36 -0.03
(-0.03%)
JPY-INR
0.58 0.00
(0.05%)

EQUITY - MARKET SCREENER

Zim Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
541400
INE518E01015
52.0221666
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ZIMLAB
44.17
356.79
EPS(TTM)
Face Value()
Div & Yield %
1.51
10
0
 

IEX Q3 PAT rises 11% YoY to Rs 119 crore
Jan 29,2026
Revenue from operations rose 10.31% year-on-year (YoY) to Rs 145.67 crore in the quarter ended 31 December 2025.

Profit before tax (PBT) jumped 12.54% YoY to Rs 156.94 crore in Q3 FY26.

On a nine-month basis, the company’s consolidated net profit rose 16.36% YoY to Rs 363.14 crore in 9M FY26, while revenue from operations increased 11.72% YoY to Rs 441.34 crore.

Meanwhile, the company’s board of directors approved the payment of an interim dividend of Rs 1.50 per equity share for the financial year 2025–26.

IEX is India's premier electricity exchange providing a nationwide, automated trading platform for physical delivery of electricity, renewable power, renewable energy certificates and energy-saving certificates.

The counter shed 0.97% to Rs 127.55 on the BSE.